Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prophylactic cranial irradiation boosts OS in advanced NSCLC

Arrieta O et al. WCLC 2018, Abstract MA08.02.

Key clinical point: Prophylactic cranial irradiation improves intracranial progression-free survival and overall survival in non–small cell lung cancer.

Major finding: Prophylactic cranial irradiation reduced the risk of CNS progression (odds ratio, 0.16).

Study details: A randomized study of 84 patients with non–small cell lung cancer.

Disclosures: Dr. Arrieta reported advisory roles or provision of expert testimony for Eli Lilly, AstraZeneca, Boehringer Ingelheim, Roche, Merck, Takeda, and Bristol-Myers Squibb, and receipt of honoraria and/or research funding from AstraZeneca, Boehringer Ingelheim, Merck, Roche, and Bristol-Myers Squibb. Dr. Nasser reported receiving research grants from Bristol-Myers Squibb, AstraZeneca, Genentech, and Merck.

Read the article.

Citation:

Arrieta O et al. WCLC 2018, Abstract MA08.02.